NCT06615882尚未招募不适用
An Exploratory Study of Intra-arterial Mechanical Angioplasty Using a SOLITAIRE™ X Stent for Refractory and Recurrent Vasospasm Mechanical Intracranial Artery DilAtation Using Stent-retriever for Cerebral Vasospasm
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 10
- 试验地点
- 2
- 主要终点
- Assess the safety (adverse events) of the interventional procedure.
研究概览
简要总结
Solitaire-x is a stent-retriever that is currently world-widely used, but is currently FDA-approved only as a revascularization device indicated for use to restore blood flow in the neurovasculature by removing thrombus for the treatment of acute ischemic stroke. Its utility for mechanical endovascular dilatation for refractory intracranial vasospasm is an off-label indication. In this reason, we designed single-arm, prospective study, which aimed to report the safety and effectiveness of Solitaire-X in CV after subarachnoid Prospective exploratory study, single arm (off label), single center study
详细描述
Prospective exploratory study, single arm (off label), single center study I. Procedure & Intervention
- Assess the presence and degree of cerebral vasospasm of the target vessel through cerebral angiography before the procedure.
- Solitaire-X stent types are selected
- During the stent-angioplasty, IA nimodipine was also infused.
- Retrieve Solitaire-X after maintaining deployment for 3 minutes.
- Additional procedures are determined through immediate post-procedure and 15-minute delayed cerebral angiography.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients≥ 19 years
- •Radiologic confirmed refractory intracranial vasospasm or due to subarachnoid hemorrhage (caused by trauma, aneurysmal rupture, spontaneous, etc.) or suspected recurrent intracrania vasospasm with the following radiological/clinical evidence (* refractory intracranial vasospasm: despite of standard treatment ≥ 50% decrease in vessel diameter compared to first angiography)
- •recurrent intracrania vasospasm: Even though chemical angioplasty was performed, radiologically cerebral vasospasm worsens (severe cerebral vasospasm(70-99%)) with worsening clinical symptoms.
- •Individuals who voluntarily signed the informed consent form to participate in this study.
排除标准
- •Pre-existing intracranial stenosis ≥ 50%
- •Patients whose condition makes further evaluation and procedures difficult
- •Exclude if Hunt and Hess grade is 4 or higher.
- •Difficult vascular access
- •History of vascular malformation, vascular anastomosis, or stent placement.
- •Distal location: Middle cerebral artery (MCA) segment M3 or below, anterior cerebral artery (ACA) segment A3 or below, posterior cerebral artery (PCA) segments P3 or P4 or below.
- •Cerebral vasospasm caused by vasculitis or dissection.
- •Hypersensitivity to medications to be used (contrast agents, vasodilators..).
- •Pregnancy or breastfeeding.
- •History of connective tissue disease or blood coagulation disorders.
- •Patients with untreated areas of subarachnoid hemorrhage.
- •Patients with symptoms due to other causes (e.g., hydrocephalus, infection, etc.).
- •Irreversible cerebral infarction in the entire vascular territory where vasospasm occurred.
- •Known allergy to medical device materials (Nitinol, Platinum, Iridium).
- •Bleeding or coagulation disorders (Platelet count < 20,000 or INR > 1.7).
- •In case of rapid worsening of cerebral hemorrhage symptoms , cerebral edema, surgery, or other urgent treatment required.
- •Subject with uncontrolled blood pressure (SBP < 100 mmHg).
- •Subject with liver dysfunction (AST/ALT > x2 upper normal limit ).
- •Subject with renal dysfunction (eGFR < 60 mL/min/1.73㎡).
- •Subject with clinically significant cardiac complications such as arrhythmia, heart failure, or myocardial infarction.
- •Subject with brain edema or elevated intracranial pressure.
- •Known current or past use of illicit drugs or alcohol abuse.
- •Requiring the administration of medications contraindicated with nimodipine.
- •Subject with systemic complications such as infection, fever, inflammation, edema, hypersensitivity, foreign body reaction, toxicity, or shock.
- •Subject with visual impairment or ocular complications.
- •Any other cases where the investigator determines that participation in the clinical trial is not possible.
结局指标
主要结局
Assess the safety (adverse events) of the interventional procedure.
时间窗: at 24 hours and 72 hours after the intervention at 3 months after Cerebral Vasospasm Onset.
次要结局
- Intervention Success Rate(at 24 hours and 72 hours after the intervention at 3 months after Cerebral Vasospasm Onset.)
- Whether additional treatment is required after intervention (; in relation to cerebral vasospasm) questionnaire(On the 1 day of the subject's intervention)
- Symptom Improvement (NIHSS)(Improvement in NIHSS at 3 months after Cerebral Vasospasm Onset.)
- Clinical Improvement (mRS)(at 24 hours and 72 hours after the intervention at 3 months after Cerebral Vasospasm Onset.)
- Degree of Cerebral Vasospasm(observed in CT cerebral angiography at 24 hours and 72 hours after the intervention.)
研究者
研究点 (2)
Loading locations...
相似试验
Unknown
不适用
Two-in-one Covered and Uncovered Metal StentExtrahepatic Bile Duct CancerLymph Node MetastasesGallbladder CancerPancreatic CancerNCT04337333Ajou University School of Medicine100
进行中（未招募）
不适用
LVIS™ Evo™ and HydroCoil® Embolic System for Intracranial Aneurysm TreatmentIntracranial AneurysmNCT04999423Microvention-Terumo, Inc.206
已完成
不适用
Prospective, Multi-center, Single-arm Study of the Auryon Laser System for Treatment of Below-the-Knee (BTK) ArteriesPeripheral Arterial DiseaseNCT05284240Midwest Cardiovascular Research Foundation60
已完成
不适用
Ultrasound-assisted or Landmark-based Intrathecal Administration of Nusinersen in Adult Patients With Spinal Muscular Atrophy (The EchoSpin Study)Anesthesia, SpinalSpinal Puncture ComplicationsUltrasonographySpinal Muscular AtrophyNCT05644899Fondazione Policlinico Universitario Agostino Gemelli IRCCS51
已完成
4 期
Clinical Investigation for Everolimus Drug Eluting StentCoronary Arterial Disease (CAD)NCT06769217Frisch Medical Device Private Limited888